Search Within

Qing Ye

Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
Groups
  1. Breast Medicine Service (25)
  2. Department of Medicine (25)
  3. GSK Faculty (25)
  4. Human Oncology and Pathogenesis Program (25)
  5. Molecular Pharmacology and Chemistry Program Faculty (25)
  6. Sloan Kettering Institute Faculty (25)

More Groups

People
  1. Neal Rosen (25)
  2. David Solit (21)
  3. Qing-Bai She (14)
  4. Sarat Chandarlapaty (8)
  5. Ayana Sawai (6)
  6. Jose Lobo (6)

More People

Years
  1. 2012 (1)
  2. 2010 (3)
  3. 2009 (3)
  4. 2008 (4)
  5. 2007 (2)
  6. 2006 (6)

More Years

Publications
  1. Cancer Research (11)
  2. EJC Supplements (3)
  3. Cancer Cell (2)
  4. Clinical Cancer Research (2)
  5. Journal of Clinical Oncology (2)
  6. Proceedings of the National Academy of Sciences of the United States of America (2)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. Pergamon-Elsevier Science Ltd (3)
  3. American Society of Clinical Oncology (2)
  4. Cell Press (2)
  5. National Academy of Sciences (2)
  6. Nature Publishing Group (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors
    Journal Article

    Iyer, G.; Morris, M. J.; Rathkopf, D.; Slovin, S. F.; Steers, M.; Larson, S. M.; Schwartz, L. H.; Curley, T.; Delacruz, A.; Ye, Q.; more...
    Cancer Chemotherapy and Pharmacology (2012)

    Fulltext@MSK | Save
  • AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
    Meeting Abstract

    Rodrik - Outmezguine, V. S.; Cao, N.; Chandarlapaty, S.; She, Q. B.; Ye, Q.; Smith, P.; Guichard, S.; Rosen, N.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors
    Journal Article

    She, Q. B.; Halilovic, E.; Ye, Q.; Zhen, W.; Shirasawa, S.; Sasazuki, T.; Solit, D. B.; Rosen, N.
    Cancer Cell (2010)

    Fulltext@MSK | Save
  • PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
    Journal Article

    Halilovic, E.; She, Q. B.; Ye, Q.; Pagliarini, R.; Sellers, W. R.; Solit, D. B.; Rosen, N.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively dependent on Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K.; Leander, K.; DeFeo-Jones, D.; Huber, H.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    Journal Article

    Pratilas, C. A.; Taylor, B. S.; Ye, Q.; Viale, A.; Sander, C.; Solit, D. B.; Rosen, N.
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save
  • Coexistent PI3K mutation in human tumors is associated with decreased dependency on mutant KRAS and MEK/ERK signaling for transformation
    Meeting Abstract

    Halilovic, E.; She, Q.; Ye, Q.; Solit, D. B.; Rosen, N.
    Cancer Research (2008)

    Fulltext@MSK | Save
  • Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling
    Journal Article

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    PLoS ONE (2008)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
    Journal Article

    Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C. L.; Sellers, W.; Rosen, N.; Solit, D. B.
    Cancer Research (2008)

    Fulltext@MSK | Save